Real-time quantitative detection of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia and its clinical application in minimal residual disease monitoring
ZHANG Rong, LIAO Jing, LI Ge, SUN Huai-Qiang, SHI Yu-Jun, YANG Ji-Yun
Department of Pediatrics, Sichuan Academy of Medical Sciences & Sichuan Provincial People′s Hospital, Chengdu 610072, China. zzrr0007@sohu.com
Abstract：OBJECTIVE: To establish a real-time reverse transcription-polymerase chain reaction (RT-PCR) for quantitative detection of E2A-PBX1 fusion gene mRNA in acute lymphoblastic leukemia (ALL) children and to explore its clinical significance in minimal residual disease monitoring and prognosis evaluation. Methods: Real-time RT-PCR was used to quantitatively detect the mRNA expression of E2A-PBX1 gene in 11 newly diagnosed ALL patients at diagnosis (11 cases), complete remission (11 cases) and periods of relapse (3 cases). Ten children with normal bone marrow cell morphology and without hematopathy or tumor diseases were used as the control group. RESULTS: The median expression levels of E2A-PBX1 fusion gene in the ALL group at diagnosis and the relapse group were significantly higher than in the control and complete remission groups (P<0.01). Compared with E2A-PBX1 negative patients on day 33 during induction of remission, the recurrence rate increased and disease free survival rate at 3 year decreased significantly in E2A-PBX1 positive patients decreased (P<0.05). CONCLUSIONS: Measurement of E2A-PBX1 levels by real-time RT-PCR is useful for monitoing minimal residual disease, prediction of relapse and individual treatment. The expression level of E2A-PBX1 gene on day 33 during induction of remission can be used for prognosis evaluation.
ZHANG Rong,LIAO Jing,LI Ge et al. Real-time quantitative detection of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia and its clinical application in minimal residual disease monitoring[J]. CJCP, 2013, 15(6): 440-443.
［1］Kager L, Lion T, Attarbaschi A, Koenig M, Strehl S, Haas OA, et al. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children［J］. Haematologica, 2007, 92(11): 1561-1564.
［2］Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia［J］. N Engl J Med, 2004, 350(15): 1535-1548.
［5］Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ′real-time′ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program［J］. Leukemia, 2003, 17(12): 2474-2486.
［6］Gabert J, Beillard E, van der velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ′real-time′ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer Program［J］. Leukemia, 2003, 17(12): 2318-2357.
［7］Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-△△Ct method［J］. Methods, 2001, 25(4): 402-408.
［8］Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonak J, Lind K, et al.The real-time polymerase chain reaction［J］. Mol Aspects Med, 2006, 27(2-3): 95-125.
［10］Scheele JS, Kolanczyk M, Gantert M, Zemojtel T, Dorn A, Sykes DB, et al. The Spt-Ada-Gcn5-acetyltransferase complex interaction motif of E2a is essential for a subset of transcriptional and oncogenic properties of E2a-Pbx1［J］.Leuk Lymphoma, 2009, 50(5): 816-828.
［12］Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008［J］. Leukemia, 2010, 24(3): 521-535.
